Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Gamma butyrobetaine has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Every molecule of endogenously made carnitine passes through gamma-butyrobetaine. The BBOX1 enzyme hydroxylates it to carnitine, mostly in liver and kidney. Loss-of-function variants in BBOX1 produce carnitine deficiency with gamma-butyrobetaine piling up behind the block, which is direct human confirmation of the pathway order. Supplementing the precursor and the product together is chemically redundant at the same step rather than complementary.
Two of the four enzymes in carnitine synthesis are ascorbate-dependent hydroxylases, and the final gamma-butyrobetaine to carnitine step is one of them. Without adequate ascorbate the iron centre oxidises and the enzyme stalls. This is why severe long-term ascorbate deficiency lowers carnitine synthesis. It does not follow that extra ascorbate above sufficiency pushes the pathway faster.
The catalytic centre of gamma-butyrobetaine dioxygenase holds a ferrous iron atom. Adequate iron status is a structural requirement for the enzyme to work at all. This is a floor effect, not a dose-response lever, and iron above sufficiency does not accelerate carnitine synthesis.
Lysine supplies the carbon skeleton for the entire carnitine pathway. Trimethyllysine, released when methylated proteins are broken down, is hydroxylated, cleaved and oxidised through to gamma-butyrobetaine. Gamma-butyrobetaine is the last intermediate before carnitine itself. Lysine availability sits several steps upstream and is not usually the rate-limiting element in a normal diet.
No methyl donation, no trimethyllysine, and therefore no gamma-butyrobetaine and no endogenous carnitine. Methionine is the source of those methyl groups through SAM. This links carnitine synthesis directly to one-carbon status, which is one reason folate, B12 and betaine also touch this pathway indirectly.
Betaine remethylates homocysteine to methionine, which sustains SAM and therefore the methyl supply that starts the carnitine pathway. The connection is real but several enzymatic steps removed from gamma-butyrobetaine itself. Nothing has measured whether betaine intake changes gamma-butyrobetaine levels in people.
Gut bacteria convert dietary carnitine to gamma-butyrobetaine and then onward to trimethylamine, which the liver oxidises to TMAO. Carnitine challenge studies in people show wide between-person variation in this output that tracks with microbiome composition. Whether any particular probiotic shifts that conversion in a useful direction has not been shown, and TMAO itself is a circulating marker rather than a demonstrated outcome. Read this as a modulating relationship worth measuring, not a benefit to claim.
Inulin was tested on the hypothesis that shifting the gut community would lower plasma TMAO. The trial did not detect a reduction, which is a failure to detect an effect rather than proof that no effect exists in any population or at any dose. The measured endpoint was a circulating marker, not a clinical outcome. It sits on the gamma-butyrobetaine route only indirectly.
The bacterial conversion of carnitine through gamma-butyrobetaine to trimethylamine is carried by a subset of gut organisms. Any substrate that changes community composition could in principle change that flux. This is mechanistic reasoning, not a measured result, and no human trial has tested resistant starch against gamma-butyrobetaine directly.
Nothing specific on file for Gamma butyrobetaine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 8 we read for Gamma butyrobetaine. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.